Choi Hyeong-Il, Kim Joonyoung, Shin In-Sik, Kim Ha-Jung
Department of Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju, Korea; BK21 Project Team, College of Veterinary Medicine, Chonnam National University, Gwangju, Korea.
BK21 Project Team, College of Veterinary Medicine, Chonnam National University, Gwangju, Korea.
Top Companion Anim Med. 2022 Sep-Oct;50:100674. doi: 10.1016/j.tcam.2022.100674. Epub 2022 May 28.
Systemic arterial hypertension is a health condition causing target organ damage (TOD) in dogs. Early and effective treatment is essential to prevent hypertensive emergencies and to reduce the risk of TOD. This study investigated the diseases underlying hypertension and compared the short-term efficacy of antihypertensive drugs in dogs. We evaluated the medical records of client-owned dogs treated with antihypertensive drugs between 2017 and 2018. The study included 75 dogs diagnosed with systemic arterial hypertension (systolic blood pressure ≥150 mmHg). The dogs were classified based on treatment with the following antihypertensive drugs: calcium channel blocker amlodipine, angiotensin-converting enzyme inhibitor ramipril, and angiotensin receptor blocker telmisartan, either as monotherapy or combination therapy (telmisartan + amlodipine or ramipril + amlodipine). Systolic blood pressure was measured using an indirect Doppler method over 4 weeks. Naturally acquired hyperadrenocorticism was the most common disorder to be diagnosed in conjunction with systemic hypertension. In the telmisartan group, the systolic blood pressure decreased more rapidly for 3 weeks compared to ramipril. The combination of telmisartan and amlodipine showed the greatest decrease in systolic blood pressure throughout the 4-week treatment period. This study is meaningful as it suggests guidelines for the use of various antihypertensive drugs in dogs.
全身性动脉高血压是一种可导致犬类靶器官损伤（TOD）的健康状况。早期且有效的治疗对于预防高血压急症和降低靶器官损伤风险至关重要。本研究调查了高血压背后的疾病，并比较了犬类抗高血压药物的短期疗效。我们评估了2017年至2018年间接受抗高血压药物治疗的宠物犬的病历。该研究纳入了75只被诊断为全身性动脉高血压（收缩压≥150 mmHg）的犬。这些犬根据使用以下抗高血压药物进行治疗进行分类：钙通道阻滞剂氨氯地平、血管紧张素转换酶抑制剂雷米普利和血管紧张素受体阻滞剂替米沙坦，单独治疗或联合治疗（替米沙坦+氨氯地平或雷米普利+氨氯地平）。使用间接多普勒法在4周内测量收缩压。自然获得性肾上腺皮质功能亢进是最常与全身性高血压一起被诊断出的疾病。在替米沙坦组中，与雷米普利相比，收缩压在3周内下降得更快。在整个4周治疗期内，替米沙坦和氨氯地平的联合使用使收缩压下降幅度最大。这项研究具有重要意义，因为它为犬类使用各种抗高血压药物提供了指导方针。
